Austar Lifesciences Limited (6118) announced a preliminary assessment indicating a profit attributable to owners of not less than RMB30 million for the year ended 31 December 2025, compared with approximately RMB16 million in 2024. The expected increase is mainly attributed to reduced operating expenses through strategic efficiency measures, higher exchange gains, and lower finance costs.

According to the company’s management, these indicators reflect optimized administrative and R&D spending, supported by organizational streamlining to enhance financial flexibility and focus on strategic growth areas. The figures remain subject to finalization and review by auditors, with official annual results slated for release in late March 2026.

Investors are advised to exercise caution when trading the company’s shares, as the figures are based on preliminary data and may be adjusted following the conclusion of the audit process.